IBN SINA declares 64% cash dividend for FY25
The board of directors made the decision in a meeting today (30 September). On the day, the company’s share price closed at Tk307.30 on the Dhaka Stock Exchange.
IBN SINA Pharmaceutical Industry—an enterprise of IBN SINA Trust—has recommended a 64% cash dividend for the 2024-25 fiscal year, continuing its upward business trend.
In the previous fiscal year, the company paid a 63% cash dividend.
The board of directors made the decision in a meeting today (30 September). On the day, the company's share price closed at Tk307.30 on the Dhaka Stock Exchange.
Keep updated, follow The Business Standard's Google news channel
According to disclosures, the company posted a consolidated net profit of Tk63.33 crore, a 5.55% decrease from Tk67.05 crore in FY 2023-24. Its consolidated earnings per share (EPS) stood at Tk20.27, down from Tk21.46 in the previous fiscal year.
On a solo basis, the company reported a net profit of Tk66.02 crore, up from Tk65.52 crore in the same period last year, with EPS rising to Tk21.13, compared to Tk20.97 in FY 2023-24. The company's net asset value (NAV) per share was Tk125.86 at the end of June 2025.
The company's annual general meeting (AGM) is scheduled for 23 November via a digital platform, with the record date on 26 October to identify eligible shareholders.
Founded in 1983 and listed on the Dhaka Stock Exchange in 1989, IBN SINA Pharmaceuticals produces a range of drugs, including herbal and Unani medicines. Its manufacturing facilities in Gazipur comprise two plants—one pharmaceutical and one natural medicine—both equipped with state-of-the-art technology.
